Please login to the form below

Not currently logged in
Email:
Password:

ESMO

This page shows the latest ESMO news and features for those working in and with pharma, biotech and healthcare.

First-line ovarian approval cements AZ’s Lynparza lead

First-line ovarian approval cements AZ’s Lynparza lead

Updated results from the SOLO-1 trial which supports the new approval were reported at this year’s ESMO conference in October and showed that 60% of patients receiving Lynparza remained

Latest news

More from news
Approximately 8 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    Combined effort. According to Dr Stefan Zimmermann from the European Society for Medical Oncology (ESMO), an increasing number of clinical trials are examining combination immunotherapies.

  • Biologic or biosimilar: what are prescribers thinking? Biologic or biosimilar: what are prescribers thinking?

    independent organisations such as ESMO, which recently published a paper supporting biosimilars as an option for sustainable cancer treatment.

  • Charting a course for expansion Charting a course for expansion

    When I met him at the annual European Society for Medical Oncology (ESMO) meeting in Copenhagen last month he explained how international expansion and oncology were key to Ipsen's plans. ... In Copenhagen, Ipsen's ESMO focus was on the CABOSUN study,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Creative review: ESMO 2018

    BLH reviews the creative concepts exhibited at the European Society for Medical Oncology (ESMO) 2018 Congress, crowning our best booth winners and giving key insights on how to develop an inspiring ... On October 19th the team from Blue Latitude Health

  • A reflection of ESMO

    Client Relationship Director Fabienne Wild from Ashfield Meetings &Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO). ... Client Relationship Director Fabienne Wild reflects on the

  • Why patient education is important in oncology

    We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed. We talked to Dr Bettina Ryll of Melanoma Patient Network

  • FALCON trial of fulvestrant for advanced breast cancer

    The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. Prof. Matthew Ellis from the Baylor College of Medicine presented the trial and talked to us about its design, the results and

  • How pembrolizumab will change the management of advanced lung cancer

    The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. The Phase III  KEYNOTE-024 trial  assessed

More from PMHub
Approximately 8 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics